Searching for genes behind Charcot-Marie-Tooth disease and its symptom differences
Looks for genes causing or changing symptoms in people with Charcot-Marie-Tooth disease.
Key facts
- Who runs it
- University of Iowa
- Where
- Ann Arbor, Aurora, Baltimore, Boston, Chapel Hill, Columbus, Hartford, Houston, Iowa City, Los Angeles, Maple Grove, Memphis, Miami, Palo Alto, Philadelphia, Rochester, and Seattle, United StatesSee the 18 sitesAlso in 5 other countries, 6 sites
- Trial code
- Registry title
- Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
- Status
- Recruiting
- People taking part
- 1,050 people, planned
- Started
- May 2010
- Expected to end
- Dec 2030
- Type of study
- Observational, 2 groups
- Record updated
- 27 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with Charcot Marie Tooth disease (CMT), a nerve disease that runs in families, and their family members. It studies genes that cause CMT or change its symptoms.
- Sex
- All sexes can join.
- Disease stage
- Patients must have nerve damage (neuropathy) shown on nerve tests, or an inherited neuropathy diagnosed by a doctor. Family members can join as controls, with or without signs of neuropathy.
- Biomarker or test result
- For the CMT1A study: a documented PMP22 duplication, or a close relative with one and a clear family link. For the new-gene (exome) study: no genetically confirmed form of CMT.
Main reasons for not taking part
- Nerve damage known to come from a non-genetic cause, such as chemotherapy (Vincristine, Taxol, Cisplatin), diabetes or alcoholism
- In the exome project: patients whose CMT type is already confirmed by a gene test
- People who do not want to take part or do not sign the consent form
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients:; o Must have demonstrated neuropathy on nerve conduction studies or a clinically diagnosed hereditary neuropathy, in the opinion of the site investigator
- Controls:; Must be a family member of a CMT patient who is enrolled in the 6602; AND one of the following:; Does not have a peripheral neuropathy, in the opinion of the site investigator; OR is suspected to have a peripheral neuropathy, but has not been examined at an INC site; CMT1A Modifier Study
- Patient has a documented PMP22 duplication; AND/OR
- Patient has a first or second degree relative (parent, child, sibling, half-sibling, aunt, uncle, grandparent, grandchild, niece, or nephew) with a documented PMP22 duplication AND a clear link between that family member and the affected patient AND a phenotype consistent with CMT1A
- A clear link is necessary for a second-degree relative. For example, if a grandparent is affected and has a PMP22 duplication, and the parent does not have any signs, symptoms, or electrophysiology consistent with CMT1A, there is no clear link
- In cases where clear links are not available, genetic testing is required for the patient or the first degree family member who is not clearly affected
Who cannot take part
- All Patients: Must not have known neuropathy from a non-genetic source, such as chemotherapies (i.e., Vincristine, Taxol, Cisplatin), diabetes, alcoholism
- CMT Exome Project Patients ONLY: Must not have a genetically confirmed form of CMT
- All Participants: Does not wish to participate or does not sign a consent form
Where in United States
Also in 5 other countries, 6 sites
- University of MichiganAnn Arbor, United StatesContact: Angela StovallTaking people
- University of Colorado HospitalAurora, United StatesContact: Study RecruiterTaking people
- Johns Hopkins UniversityBaltimore, United StatesContact: Simone ThomasTaking people
- Harvard (Massachusetts General Hospital)Boston, United StatesContact: Lauren PoliticaTaking people
- University of North CarolinaChapel Hill, United StatesContact: Caroline SummerourTaking people
- Nationwide Children's HospitalColumbus, United StatesContact: Stephanie DavisTaking people
- Connecticut Children's Medical CenterHartford, United StatesContact: Jennifer Twatchtman-BassettTaking people
- Houston Methodist HospitalHouston, United StatesContact: Samia SaadTaking people
- University of IowaIowa City, United StatesContact: Tiffany Grider, MS, CGCTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Marcela Arenas SanchezTaking people
- University of MinnesotaMaple Grove, United StatesContact: Mia FreibergTaking people
- St. Jude Children's Research HospitalMemphis, United StatesContact: Colin QuillivanTaking people
- University of MiamiMiami, United StatesContact: Liuba AlonsoTaking people
- Stanford UniversityPalo Alto, United StatesContact: Michelle JepsenTaking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Sabrina Yum, MDTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Daya StevensTaking people
- University of RochesterRochester, United StatesContact: Janet SowdenTaking people
- Seattle Children's HospitalSeattle, United StatesContact: Shawna FeelyTaking people
About the trial
What the trial wants to find out
This project includes two projects. One is looking for new genes that cause Charcot Marie Tooth disease (CMT). The other is looking for genes that do not cause CMT, but may modify the symptoms a person has.
The 2 groups in the trial
- CMT1A
Families/people with genetically defined CMT1A
- Genetically undefined CMT
Families/people with genetically undefined CMT with common causes ruled out.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Genetics of Charcot Marie Tooth Disease (CMT) - Modifiers of CMT1A, New Causes of CMT
- Plain-language title
- Searching for genes behind Charcot-Marie-Tooth disease and its symptom differencesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 27 October 2026